Targeted radionuclide therapy

Medical Physics

Volumn 35, Issue 7, 2008, Pages 3062-3068

  Williams, Lawrence E ^a   DeNardo, Gerald L ^b   Meredith, Ruby F ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

Absorbed dose; Antibodies; Radionuclide therapy

Indexed keywords

ANTIBODIES; CHEMOTHERAPY; LIPOSOMES; TOXICITY; TUMORS;

ABSORBED DOSE; CLINICAL APPLICATION; MALIGNANT TISSUES; PATIENT SPECIFIC; PET/CT SCANNERS; RADIONUCLIDE THERAPY; TARGETED RADIONUCLIDE THERAPIES; TREATMENT EFFICIENCY;

RADIOISOTOPES;

ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIBODY IN 111 CT84.66; IBRITUMOMAB TIUXETAN; INDIUM 111; LIPOSOME; MORPHOLINE DERIVATIVE; NANOPARTICLE; NUCLEOTIDE; OCTREOTIDE; RADIOISOTOPE; SODIUM IODIDE; TOSITUMOMAB I 131; YTTRIUM 90;

ARTICLE; B CELL LYMPHOMA; BONE MARROW; CANCER RADIOTHERAPY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; LIVER CANCER; LYMPHOMA; PHANTOM; PRIORITY JOURNAL; RADIATION ABSORPTION; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

EID: 46149100279     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.2938520     Document Type: Article

References (37)

1. A. J. Jacobs, M. Fer, F. M. Su, H. Breitz, J. Thompson, H. Goodgold, J. Cani, J. Heap, and P. Weiden, " A phase I trial of rhenium-186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response.," Obstet. Gynecol. (N.Y., NY, U. S.) 82, 586-593 (1993).
2. P. Riva, A. Arista, V. Tison, C. Sturiale, G. Francheschi, A. Spinelli, N. Riva, M. Casi, G. Moscatelli, and M. Frattarelli, " Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent tumors.," Cancer 73, 1076-1082 (1994). 0008-543X
3. B. Shapiro, J. C. Sisson, D. M. Wieland, T. J. Mangner, S. M. Zempel, E. Mudgett, M. D. Gross, J. E. Carey, K. R. Zasadny, and W. H. Beierwaltes, " Radiopharmaceutical therapy of malignant pheochromocytoma with 131I metaiodobenzylguanidine: Results from ten years of experience.," J. Nucl. Biol. Med. 35, 269-276 (1991). 0368-3249
4. A. Frilling, F. Weber, V. Cicinnati, and C. Broelsch, " Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms.," Exp. Rev. Endocrinology Metabolism 2, 517-527 (2007).
5. G. L. DeNardo, A. Natarajan, S. Hok, J. Perkins, M. Cosman, S. J. DeNardo, F. C. Lightstone, G. L. Mirick, L. A. Miers, and R. L. Balhorn, " Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.," J. Nucl. Med. 48, 1338-1347 (2007). 0161-5505
6. B. J. Hicke, A. W. Stephens, T. Gould, Y. -F. Chang, C. K. Lynott, J. Heil, S. Borkowski, C. -S. Hilger, G. Cook, S. Warren, and P. G. Schmidt, " Tumor targeting by an aptamer.," J. Nucl. Med. 47, 668-678 (2006). 0161-5505
7. T. A. Waldmann, " Monoclonal antibodies in diagnosis and therapy.," Science 252, 1657-1662 (1991). 0036-8075
8. J. W. Park, " Liposome-based drug delivery in breast cancer treatment.," Breast Cancer Res. 4, 95-99 (2002). 1465-5411
9. J. F. Kukowska-Latallo, K. A. Candido, Z. Cao, S. S. Nigavekar, I. J. Majoros, T. P. Thomas, L. P. Balogh, M. K. Khan, and J. R. Baker, Jr., " Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.," Cancer Res. 0008-5472 10.1158/0008-5472.CAN-04-3921 65, 5317-5324 (2005).
10. G. Liu, S. Dou, G. Mardirossian, J. He, S. Zhang, X. Liu, M. Rusckowski, and D. J. Hnatowich, " Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, as synthetic DNA analogue.," Clin. Cancer Res. 12, 4958-4964 (2006). 1078-0432
11. R. J. Lewandowski, K. G. Thurston, J. E. Goin, C. Y. Wong, V. L. Gates, M. Van Buskirk, J. F. Geschwind, and R. Salem, " Y 90 microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted absorbed doses of 135-150 Gy as measured by 18F fluorodeoxyglucose positron emission tomography and computer tomographic imaging.," J. Vasc. Interv. Radiol. 16, 1641-1651 (2005). 1051-0443
12. A. S. Kennedy, D. Coldwell, C. Nutting, R. Murthy, D. E. Wertman, Jr., S. P. Loehr, C. Overton, S. Meranze, J. Niedzwecki, and S. Sailer, " Resin Y 90 -microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience.," Int. J. Radiat. Oncol., Biol., Phys. 0360-3016 10.1016/j.ijrobp.2005.12.051 65, 412-425 (2006).
13. V. Kenanova, T. Olafsen, L. E. Williams, N. H. Ruel, J. Longmate, P. J. Yazaki, J. E. Shively, D. Colcher, A. A. Raubitschek, and A. M. Wu, " Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: Optimal pharmacokinetics for therapy.," Cancer Res. 67, 718-726 (2007). 0008-5472
14. G. A. Wiseman, C. A. White, R. B. Sparks, W. D. Erwin, D. A. Podoloff, D. Lamonica, N. L. Bartlett, J. A. Parker, W. L. Dunn, S. M. Spies, R. Belanger, T. L. Witzig, and B. R. Leigh, " Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.," Crit. Rev. Oncol. Hematol. 39, 181-194 (2001). 1040-8428
15. J. M. Vose, R. L. Wahl, M. Saleh, A. Z. Rohatiner, S. J. Knox, J. A. Radford, A. D. Zelenetz, G. F. Tidmarsh, R. J. Stagg, and M. S. Kaminski, " Multicenter phase II study of iodine I-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma.," J. Clin. Oncol. 18, 1316-1323 (2000). 0732-183X
16. J. Y. C. Wong, S. Shibata, L. E. Williams, C. S. Kwok, A. Liu, D. Z. Chu, D. M. Yamauchi, S. Wilcznski, D. N. Ikle, A. M. Wu, P. J. Yazaki, J. E. Shively, J. H. Doroshow, and A. A. Raubitschek, " A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.," Clin. Cancer Res. 9, 5842-5852 (2003). 1078-0432
17. B. Emami, J. Lyman, A. Brown, L. Coia, M. Goitein, J. E. Munzenrider, B. Shank, L. J. Solin, and M. Wesson, " Tolerance of normal tissue to therapeutic irradiation.," Int. J. Radiat. Oncol., Biol., Phys. 21, 109-122 (1991). 0360-3016
18. G. L. DeNardo, S. J. DeNardo, S. Shen, D. A. DeNardo, G. R. Mirick, D. J. Macey, and K. R. Lamborn, " Factors affecting 131-I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.," J. Nucl. Med. 40, 1317-1326 (1999). 0161-5505
19. J. A. Siegel, B. W. Wessels, E. E. Watson, M. G. Stabin, H. M. Vriesendorp, E. W. Bradley, C. C. Badger, A. B. Brill, C. S. Kwok, D. R. Stickney, K. F. Eckermann, D. R. Fisher, D. J. Buchsbaum, and S. E. Order, " Bone marrow dosimetry and toxicity in radioimmunotherapy., " Antibody, Immunoconjugates, Radiopharm. 3, 213-233 (1990).
20. M. G. Stabin, " MIRDOSE: Personal computer software for internal absorbed dose assessment in nuclear medicine.," J. Nucl. Med. 37, 538-546 (1996). 0161-5505
21. M. G. Stabin, R. B. Sparks, and E. Crowe, " OLINDA/EXM: The second-generation personal computer software for internal absorbed dose assessment in nuclear medicine.," J. Nucl. Med. 46, 1023-1027 (2005). 0161-5505
22. L. E. Williams, A. Liu, A. A. Raubitschek, and J. Y. C. Wong, " A method for patient-specific absorbed dose estimation for internal beta emitters.," Clin. Cancer Res. 5, 3015s-3019s (1999). 1078-0432
23. G. Akabani, W. G. Hawkins, M. B. Eckblade, and P. K. Leichner, " Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution.," J. Nucl. Med. 38, 308-314 (1997). 0161-5505
24. C. H. Holdsworth, M. Dahlbom, A. Liu, L. Williams, C. S. Levin, M. Janecek, and E. J. Hoffman, " Expanding the versatility of a more accurate accelerated Monte Carlo simulation for 3D PET: Data correction of PET emission scans using 124-I.," Nuclear Science Symposium Conference Record 2001 IEEE (2002), Vol. 4, pp. 2105-2109.
25. D. A. Goodwin, " Tumor pretargeting: Almost the bottom line.," J. Nucl. Med. 36, 876-879 (1995). 0161-5505
26. D. M. Goldenberg and R. M. Sharkey, " Novel radiolabeled antibody conjugates.," Oncogene 26, 3734-3744 (2007). 0950-9232
27. O. Linden, J. Kurkus, M. Garkavij, E. Cavallin-Stahl, M. Ljungberg, R. Nilsson, T. Ohlsson, B. Sandberg, S. -E. Strand, and J. Tennvall, " A novel platform for radioimmunotherapy: Extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.," Cancer Biother. Radiopharm. 20, 457-466 (2005). 1084-9785
28. S. Welt, G. Ritter, C. Williams, Jr., L. S. Cohen, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny, " Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.," Clin. Cancer Res. 9, 1347-1353 (2003). 1078-0432
29. L. E. Williams, A. Liu, D. M. Yamauchi, G. Lopatin, A. A. Raubitschek, and J. Y. C. Wong, " The two types of correction of absorbed dose estimates for internal emitters.," Cancer 94, 1231-1234 (2002). 0008-543X
30. D. J. Macey, L. E. Williams, H. B. Breitz, A. Liu, T. K. Johnson, and P. B. Zanzonico, A Primer for Radioimmunotherapy and Radionuclide Therapy AAPM Report No. 71 (Medical Physics, Madison, WI, 2001).
31. K. F. Koral, Y. Dewaraja, L. A. Clarke, J. Li, R. Zasadny, S. G. Rommelfanger, I. R. Francis, M. S. Kaminski, and R. L. Wahl, " Tumor-absorbed dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's Lymphoma: Preliminary report.," Cancer Biother. Radiopharm. 15, 347-355 (2000). 1084-9785
32. C. Hindorf, O. Linden, L. Stenberg, J. Tennvall, and S. -E. Strand, " Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.," Clin. Cancer Res. 1, 4003S-4006S (2003). 1078-0432
33. L. E. Williams, R. B. Duda, R. T. Proffitt, B. G. Beatty, J. D. Beatty, J. Y. C. Wong, J. E. Shively, and R. J. Paxton, " Tumor uptake as a function of tumor mass: A mathematic model.," J. Nucl. Med. 29, 103-109 (1988). 0161-5505
34. D. J. Macey, S. J. DeNardo, G. DeNardo, J. L. Goodnight, and M. W. Unger, " Uptake of In-111 labeled monoclonal antibody ZME018 as a function of tumor size in a patient with melanoma.," Am. J. Physiol. Imaging 3, 1-6 (1988). 0885-8276
35. G. Riethmuller, E. Schneider-Gadicke, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, H. Pichlmaier, H. Hirche, R. Pichlmayr, P. Buggisch, and J. Witte, " Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma.," Lancet 343, 1177-1183 (1994). 0140-6736
36. J. Carlsson, E. Aronsson Forsell, S. O. Hietala, T. Stigbrand, and T. Tennvall, " Tumor therapy with radionuclides: Assessment of progress and problems.," Radiother. Oncol. 0167-8140 10.1016/S0167-8140(02)00374-2 66, 107-117 (2003).
37. Reprinted by permission of the Society of Nuclear Medicine from J. Y. C. Wong, G. E. Thomas, D. Yamauchi, L. E. Williams, T. L. Odom-Maryon, A. Liu, J. M. Esteban, M. Neumaier, S. Dresse, A. M. Wu, F. J. Primus, J. E. Shively, and A. A. Raubitschek, " Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.," J. Nucl. Med. 38, 1951-1959 (1997).